Oxford Pharmascience to start pilot clinical study for Oxpzero Ibuprofen
Wednesday, August 12, 2015
Oxford Pharmascience Group Plc Preliminary pharmacokinetic data and initiation of pilot clinical study to demonstrate improved GI profile for oxpzero ibuprofen.
Company has commenced dosing in second phase of study.
Headline results on second phase are expected to be released in q4 2015, along with complete pk data and further taste masking assessments.
reuters.com
